FDA approves second generic naloxone spray

Jun 22, 2022 - 02:24 PM
fda-product-update

The Food and Drug Administration approved the second generic naloxone nasal spray, an emergency treatment for known or suspected opioid overdose. The agency approved the first generic naloxone nasal spray in 2019.

Related News Articles

Headline
AHA submits comments on draft drug shortage legislation to Senate Finance Committee leaders 
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
Drug Prices and Shortages Jeopardize Patient Access to Quality Hospital Care
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
ASHP reports record high number of drug shortages 
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
HHS proposes policies to prevent drug shortages
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
AHA recommends legislative action to address chronic drug shortages 
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
AHA-supported drug shortages bill introduced in House
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…